Top

Annals of Nuclear Medicine

Published in:

01-07-2021 | Prostate Cancer | Original Article

Therapeutic efficacy of ²²⁵Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy

Authors: Ishita Sen, Parul Thakral, Priya Tiwari, Vineet Pant, Subha Shankar Das, Divya Manda, Vinod Raina

Published in: Annals of Nuclear Medicine | Issue 7/2021

Abstract

Objectives

²²⁵Ac-PSMA-617 therapy has shown good response in many recent studies. We report our experience of targeted alpha therapy with ²²⁵Ac-PSMA-617 in mCRPC patients who have failed therapy with taxanes.

Materials and methods

Thirty-eight patients with CRPC with progressive disease following at least one taxane-based chemotherapy received ²²⁵Ac-PSMA-617 between July 2017 and Nov 2019. Primary end point was a composite 50% PSA and radiological response. Secondary endpoints were PFS, OS, and changes in QOL. The differences in outcomes between patients with skeletal and lymph-node metastases versus those with visceral metastases were also studied.

Results

A composite response by predetermined criteria was observed in 25 (66%) of 38 patients. The median PFS was 8 months (95% CI 5.3–10.6 months). Median overall survival was 12 months (95% CI 9.1–14.9) with 16 patients alive at the time of censorship. There was no difference in response rates or survival statistics between patients with visceral metastases versus those with only bone and lymph-node metastases (Chi-square 1.51, df 1, Sig 0.218). The most common adverse effect was xerostomia. On the QOL Symptom score, Pain, Fatigue Insomnia, and constipation showed a significant improvement as compared to baseline.

Conclusions

²²⁵Ac-PSMA-617 is a safe and tolerable treatment option for mCRPC that demonstrates marked anti-tumour activity with improvement in quality of life even in patients of metastatic CRPC who have been previously treated with taxane-based chemotherapy.

Data could not be received for patient 11.

Cui PF, Cong XF, Gao F, Yin JX, Niu ZR, Zhao SC, et al. Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients. World J Clin Cases. 2020;8(1):54–67. https://doi.org/10.12998/wjcc.v8.i1.54.CrossRefPubMedPubMedCentral

Van der Doelen MJ, Mehra N, Smits M, van Oort IM, Janssen MJR, et al. Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients. J Clin Oncol. 2018;36(6_suppl):344. https://doi.org/10.1200/JCO.2018.36.6_suppl.

West TA, Kiely BE, Stockler MR. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials. Eur J Cancer. 2014;50:1916–24. https://doi.org/10.1016/j.ejca.2014.04.004.CrossRefPubMed

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working Group 3. J Clin Oncol. 2016;34(12):1402–18. https://doi.org/10.1200/JCO.2015.64.2702.CrossRefPubMedPubMedCentral

Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–704. https://doi.org/10.1200/JCO.2011.35.8648.CrossRefPubMedPubMedCentral

Eiber M, Herrmann K, Calais J, Hadaschihk B, Giesel F, Hartenbach M, et al. Prostate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59(3):469–78. https://doi.org/10.2967/jnumed.117.198119.CrossRefPubMed

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W. Targeted alpha therapy of mCRPC with ²²⁵Actinium-PSMA-617: Dosimetry estimate and empirical dose finding. J Nucl Med. 2017;58(10):1624–31. https://doi.org/10.2967/jnumed.117.191395.

Shukurov R, Veliyev M, Dadashov Z, İsayev J, Novruzov F. Labeling process and quality control results of ²²⁵Ac-PSMA-617 for targeted alpha particle therapy for metastatic prostate cancer. J Nucl Med. 2019;60(supplement 1):1611.

Common Terminology Criteria for Adverse Events (CTCAE) (2017) Version 5.0 Published: November 27. U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute

10.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef

11.

Van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.CrossRef

12.

Cleeland CS, Ryan KM. Pain assesment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994;23:129–38.PubMed

13.

Schwartz LH, Litière S, Elisabeth de Vries, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1–Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. https://doi.org/10.1016/j.ejca.2016.03.081.

14.

Fuerecker B, Knorr K, Beheshti A, Seidl C, D’Alessandrai C, et al. Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA. J Med Imaging Radiat Sci. 2019;50(1):S20–1. https://doi.org/10.1016/j.jmir.2019.03.066.

15.

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, et al. ²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129–38. https://doi.org/10.1007/s00259-018-4167-0.CrossRefPubMed

16.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. https://doi.org/10.1056/NEJMoa041318.CrossRefPubMed

17.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. https://doi.org/10.1056/NEJMoa040720.CrossRefPubMed

18.

De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. https://doi.org/10.1016/S0140-6736(10)61389-X.CrossRefPubMed

19.

De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. https://doi.org/10.1056/NEJMoa1014618.CrossRefPubMedPubMedCentral

20.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60. https://doi.org/10.1016/S1470-2045(14)71205-7.CrossRefPubMed

21.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. https://doi.org/10.1056/NEJMoa1207506.CrossRefPubMed

22.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoa1405095.CrossRefPubMedPubMedCentral

23.

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23. https://doi.org/10.1056/NEJMoa1213755.CrossRefPubMed

24.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. for the AFFIRM investigators, increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. https://doi.org/10.1056/NEJMoa1207506.CrossRefPubMed

25.

Hofman M, Violet JA, Hicks RJ, Ferdinandus J, Thang SP, Iravani A, et al. Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Clin Oncol. 2019;37(7_suppl):228. https://doi.org/10.1200/JCO.2019.37.7_suppl.228.

26.

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Frederik L Giesel FL, et al. Targeted Alpha Therapy of mCRPC with ²²⁵Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control. J Nucl Med. 2018;59(5):795–802. https://doi.org/10.2967/jnumed.117.203539.

27.

Gofrit ON, Frank S, Meirovitz A, Nechushtan H, Orevi M. PET/CT With ⁶⁸Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer. Clin Nucl Med. 2017;42(1):1–6. https://doi.org/10.1097/RLU.0000000000001424.

Title: Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
Authors: Ishita Sen
Parul Thakral
Priya Tiwari
Vineet Pant
Subha Shankar Das
Divya Manda
Vinod Raina
Publication date: 01-07-2021
Publisher: Springer Singapore
Keywords: Prostate Cancer
Metastasis
Prostate Cancer
Cytostatic Therapy
Published in: Annals of Nuclear Medicine / Issue 7/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-021-01617-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Therapeutic efficacy of ²²⁵Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy

Abstract

Objectives

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2021

Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)

Prognostic value of 18F-FDG PET/CT with texture analysis in patients with rectal cancer treated by surgery

Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors

The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review

Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma

Measuring myocardial blood flow with 82rubidium using Gjedde–Patlak–Rutland graphical analysis